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Objectives: The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Mus-
culoskeletal Diseases (ESCEO) sought to revisit the 2014 algorithm recommendations for knee osteoarthritis
(OA), in light of recent efficacy and safety evidence, in order to develop an updated stepwise algorithm that
provides practical guidance for the prescribing physician that is applicable in Europe and internationally.
Methods: Using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) pro-
cess, a summary of evidence document for each intervention in OA was provided to all members of an ESCEO
working group, who were required to evaluate and vote on the strength of recommendation for each inter-
vention. Based on the evidence collected, and on the strength of recommendations afforded by consensus of
the working group, the final algorithm was constructed.
Results: An algorithm for management of knee OA comprising a stepwise approach and incorporating con-
sensus on 15 treatment recommendations was prepared by the ESCEO working group. Both “strong” and
“weak” recommendations were afforded to different interventions. The algorithm highlights the continued
importance of non-pharmacological interventions throughout the management of OA. Benefits and limita-
tions of different pharmacological treatments are explored in this article, with particular emphasis on safety
issues highlighted by recent literature analyses.
Conclusions: The updated ESCEO stepwise algorithm, developed by consensus from clinical experts in OA and
informed by available evidence for the benefits and harms of various treatments, provides practical, current
guidance that will enable clinicians to deliver patient-centric care in OA practice.
© 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license.
(http://creativecommons.org/licenses/by-nc-nd/4.0/)Keywords:
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Knee osteoarthritisCS, chondroitin sulfate; IAHA, intra-articular hyaluronic acid; NSAIDs, non-steroidal anti-inflammatory drugs; OA, osteoar-
e; SYSADOAs, symptomatic slow-acting drugs for osteoarthritis.
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Osteoarthritis (OA) is the most common form of arthritis, and is
characterized by joint pain and stiffness leading to functional decline
and loss in participation and quality of life [1,2]. The incidence of OA
is rising due to the aging population and an increase in obesity [3].
Knee OA is the most common OA localization, and symptomatic knee
OA is highly prevalent among people aged over 50 years, affecting
more than 250 million people worldwide [4]. OA is a leading cause of
pain in older people, and pain of the hip and knee results in physical
disability and an increased risk of all-cause mortality [2,5]. Hip and
knee OA together are the eleventh highest contributor to global dis-
ability: the years of life lived with OA-related disability increased by
64% from 1990 to 2010 reaching 17 million [6]. OA is a progressive
disorder, with different degrees of severity, that requires long-term
management with various treatment options over the course of the
disease. The goals of treatment for OA are to reduce symptoms and
ultimately slow disease progression, which may in turn reduce the
impact of OA on the patient’s mobility and quality of life, with conse-
quent reduction in healthcare resource needs.
In 2014, the European Society for Clinical and Economic Aspects of
Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO)
published recommendations for the management of knee OA in the
form of a treatment algorithm that provides practical guidance for
the prioritization of interventions and guides physicians through pro-
gressive, logical steps [7]. The ESCEO algorithm differed from previ-
ous guideline development which had analyzed the level of evidence
behind each intervention without prioritizing the interventions in a
given sequence [811]. While the ESCEO guidelines were written
predominantly from a European perspective, since 2014, the ESCEO
algorithm has been well-received internationally, and endorsed by
many societies worldwide with translation, adaptation to the local
context, and publication in China, Russia and South-East Asia
[1215]. An update to the ESCEO algorithm was published in 2016 as
a supplement to this journal, when further data for selected pharma-
cological interventions in OA and from real world analyses had
become available [16]. Since publication of the 2014 algorithm, con-
siderable new evidence has been published, particularly regarding
the safety of many medications commonly used to treat OA. The
ESCEO itself identified a need for comprehensive safety data, and
commissioned several meta-analyses on different classes of anti-OA
medications [1721]. While conducting the safety meta-analyses, the
extensive literature reviews revealed a lack of reporting of AE data
and inconsistencies in the data reported, and a need for precise guid-
ance on the reporting of AEs in clinical trials was identified. As a
result, a recent consensus statement from the ESCEO provides spe-
cific, clear, practical and standardized guidance on the reporting of
AE data in manuscripts reporting the outcomes of clinical trials
assessing drugs for OA [22].
In this update, a working group of the ESCEO has revisited the
ESCEO treatment algorithm recommendations in light of recent effi-
cacy and safety evidence, and has developed new recommendations
based upon application of the Grading of Recommendations Assess-
ment, Development and Evaluation (GRADE) process [23]. To this
end, the ESCEO working group now delivers an updated stepwise
algorithm of recommendations in order to provide practical, current
guidance that will enable clinicians to deliver patient-centric care in
OA practice.
Methods
The ESCEO gathered an international working group of 18 mem-
bers comprising rheumatologists, specialists in physical medicine and
rehabilitation, clinical epidemiologists, endocrinologists, pharmacolo-
gists, orthopedic surgeons, geriatricians, specialists in public health
and health economics, research scientists and patient representatives,all of whom are experienced in the performance, analysis and inter-
pretation of clinical trial evidence related to OA. All experts in the
working group were invited to a meeting held on March 20, 2018 in
Geneva, Switzerland, where some members of the working group
(OB, EC, GH-B. FR, DU, GH) gave presentations on a full review of the
ESCEO 2014 algorithm recommendations and specific areas of knee
OA treatment that required particular attention in light of new data
on efficacy and safety. After the presentations, a comprehensive dis-
cussion was held within the group to address the areas requiring
attention. Some members of the working group (NV, GH, EC, OB)
were presented with the task of performing a full literature search on
all interventions considered in the last algorithm and any other inter-
ventions subsequently approved or made available for knee OA, i.e.
covering the period from publication of the last guidance document
(2014) through to September 30, 2018. The purpose of the literature
search was to identify the most recent, complete and representative
systematic reviews and meta-analyses for each intervention that
could support the development of specific questions to the working
group with the intention of building the new version of the ESCEO
algorithm recommendations. Particularly relevant randomized con-
trolled trials (RCTs), especially if they were not included in any meta-
analysis as yet, or other forms of clinical evidence, were also identi-
fied in the literature search. The search was conducted using a combi-
nation of keywords and controlled terms describing the study types
(meta-analysis, systematic review, clinical trial) and the disease (OA).
The following electronic databases were searched: MEDLINE (via
Ovid), EMBASE, the Cochrane Central Register of Controlled Trials
(Ovid CENTRAL) and the Cochrane Database of Systematic Reviews
(CDSR via Ovid), adapting the search terms to each database vocabu-
lary. When data on efficacy and/or safety outcomes were appropriate
for analysis, the systematic reviews/meta-analyses were assessed
using the GRADE system by two members of the working group (NV,
GH) (http://www.gradeworkinggroup.org/) [23,24]. The findings of
network meta-analyses were assessed by GRADE only if direct com-
parisons were reported. If this condition was not fulfilled, their gen-
eral findings could not be analyzed by GRADE since the methods are
not well developed as yet; in this case, their results were only
reported descriptively. GRADE evidence profiles and quality assess-
ments for suitable publications were created using the GRADEpro
software (https://gradepro.org/) [25].
A Summary of Evidence document for each intervention was pro-
vided to all members of the working group and consisted of the fol-
lowing sections: (a) 2014 Status: a summary of the considerations
that were included in the 2014 algorithm publication and led to the
algorithm construction at that time, to be assessed before the
updated literature search; (b) 20142018 Search Results: a descrip-
tion of the selected recent findings in the new literature search; (c)
GRADE Evidence Profiles: consisting of the tables generated using the
GRADE software for new qualifying studies and including the sum-
mary of findings and quality assessment by an explicit judgment of
factors that determine the quality of evidence (certainty assessment)
and the magnitude of effect for each outcome; (d) References.
All members of the working group were provided with the GRADE
Grid (electronically) for all questions derived from the Summaries of
Evidence. Recommendations were based on an integrated assessment
of past and current evidence, including balance and magnitude of
effect for important outcomes of both benefits and harms, quality of
evidence (the higher the quality of evidence, the more likely a strong
recommendation), value and preferences, costs (even if a formal
assessment of costs was not provided to the panel members) [26],
and position of the intervention within the algorithm. The instruc-
tions to the working group, the final Summary of Evidence docu-
ments and the GRADE Grid, are presented in Appendices A, B and C,
respectively (electronic supplementary material). The votes of the
ESCEO working group members were expressed anonymously to
allow for free expression of views.
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75% of the members of the working group were either “strongly” or
“weakly” in favour or against the recommendation [26,27]. If this cri-
terion was not met, a consensus could not be defined and a “No rec-
ommendation” was to be attributed to the question/intervention;
however, this was never necessary. The strength of recommendation
was determined as “strong” rather than “weak” if at least 75% of the
working group members rated a recommendation as “strong”.
Based on the evidence collected and on the strength of the recom-
mendations by the working group (results of the GRADE process are
presented in Table 1), the final algorithmwas built and the draft man-
uscript prepared. This was submitted to all members of the working
group through repeated rounds of comment and revision until a final
version of the manuscript was accepted by all members of the work-
ing group.
Results
Non-pharmacological treatment: basic principles and core set
The combination of treatment modalities including non-pharma-
cological and pharmacological intervention remains key to the man-
agement of knee OA and it is the basic principle in the ESCEO
algorithm, which provides advice for treatment prioritization and
possible combination.
The core set of initial and continued measures that was endorsed
in the ESCEO 2014 algorithm is still valid: information/education;
weight loss if overweight [28]; and an exercise program (i.e. aerobic,
strengthening, or resistance exercises) [7,2932]. However, the
working group acknowledges that there remains some debate
regarding the optimal modalities of these approaches, their real effect
size (ES) on pain and joint function [33,34], and their feasibility in the
long term [35]. Further, it is recognized that such recommendations
on exercise for knee OA also apply to subjects aged 7080 years,
even though there is a paucity of data on the benefit: risk of exercise
and diet programs among older populations, particularly those aged
75 years [36].
GRADE recommendation: (1) The ESCEO working group affords a
strong recommendation to the application of a core set comprising:
information access/education, weight loss and an exercise program,
which is applicable throughout the management of knee OA.
Other non-pharmacological interventions
In the 2014 version of the ESCEO algorithm, other non-pharmaco-
logical treatments for knee OA were briefly reviewed [7]. It was rec-
ommended that, in Step 1 of background treatment and after
adhering to the basic principle and core set, patients should be
referred to a physical therapist or another specialist for assessment of
whether correction for varus/valgus malalignment is needed [37,38].
A correction with knee braces seems to be preferred to wedged
insoles [38]. Moreover, during this step or afterwards and across steps
at any time, this working group maintains the recommendation that
assessment of whether other physical interventions may be useful for
additional symptom relief in combination with pharmacological
interventions should be carried out. A comprehensive review of non-
pharmacological interventions goes beyond the scope of this article
and was, in the meantime, performed by several specialized groups
[10,29,30,32,3941]. A non-comprehensive list of possible non-phar-
macological interventions, supported by variable degrees of evidence,
is listed in Fig. 1.
While the ES of non-pharmacological modalities may be measured
as low, these interventions are generally considered as safe [10].
However, in practice, non-pharmacological treatments are under-uti-
lized. Healthcare providers (HCPs: rheumatologists, orthopedic sur-
geons, physical therapists and general practitioners) report three
main barriers impeding non-pharmacological, non-surgical care forpatients with knee and hip OA including: lack of expertise of the
healthcare professional (knowledge and skills); lack of evidence-
based treatment (e.g. regarding weight management, and the inten-
sity and dosage of physical exercise in the core set); and suboptimal
organization of care [42]. To overcome these barriers, education
focused on initiating and supporting lifestyle changes, promotion of
interventions according to evidence-based recommendations, and
improved organization of care is proposed [42]. For the patient, bar-
riers also exist particularly for physical activity and exercises since
patients are often experiencing a lot of pain, and preliminary pain
relief is mandatory to allow for practicing exercises and physical
activity. Barriers may be overcome through positive exercise experi-
ences, changing beliefs, knowledge and attitudes, and by having the
support of HCPs and social services. Lastly, the program should be
personalized and adjusted to the characteristics of the patient [31]
and their environment [43].
Pharmacological treatment
Step 1: background treatment
Paracetamol (acetaminophen) has been widely recommended as a
first-line step for rescue analgesia, despite the fact that the effect of
paracetamol on symptoms is minimal [811,44]. The ESCEO doubt-
fully recommended paracetamol on a regular basis in the 2014 algo-
rithm version [7]. Paracetamol has a minimal ES on pain of 0.14 (95%
confidence interval [CI] 0.050.22), which translates to no detectable
clinical effect (<0.2), and no significant effect on stiffness and physical
function in patients with knee OA [4447]. Recent concerns over the
safety profile of paracetamol raise questions over its routine chronic
use, due to increasing evidence of gastrointestinal (GI), cardiovascular
(CV), hepatic and renal adverse events (AEs) [48]. A systematic litera-
ture review of observational studies identified a considerable degree
of liver and gastrointestinal toxicity associated with paracetamol,
especially at the upper end of standard analgesic doses (up to 4 g/
day) [49]. From 2 mortality studies, 1 showed a dose-response and
increased relative rate of mortality from 0.95 (95% CI 0.92, 0.98) to
1.63 (95% CI 1.58, 1.68) [50], and the other a significantly increased
standardized mortality ratio for patients prescribed paracetamol ver-
sus those not prescribed paracetamol [51]. Four studies reporting CV
events all showed a dose-response with 1 reporting an increased risk
ratio for all CV AEs from 1.19 (95% CI 0.81, 1.75) (325650mg/week)
to 1.68 (95% CI 1.10, 2.57) (>4875mg/week) [52]. One study reported
a dose-response increase in upper GI AEs (ulcers, hemorrhages) with
increased relative rate from 1.11 (95% CI 1.04, 1.18) to 1.49 (95% CI
1.34, 1.66) [50]. Three out of 4 studies reported a dose-response effect
on renal function, with lifetime cumulative intake of 100499 g asso-
ciated with increased odds of reduced renal function (odds ratio [OR]
1.80; 95% CI 1.02, 3.18) [53], and a dose-response increase in OR of
30% decrease in estimated glomerular filtration rate (eGFR) and
0.3mg/dL increase in serum creatinine [54].
A systematic review and meta-analysis found 3 RCTs that evalu-
ated the results of liver function tests to detect AEs with paracetamol
in participants with hip and knee OA. Participants taking paracetamol
were nearly 4 times more likely to have abnormal results on liver
function tests than participants taking placebo (weighted mean dif-
ference [WMD] 3.8; 95% CI 1.9, 7.4) [55]. Reports of hepatotoxicity
and acute liver failure associated with chronic paracetamol dosing
are a further cause of concern with widespread, unrestricted paracet-
amol use [56,57].
GRADE recommendations: Based on questionable efficacy and con-
firmed safety issues, (2) The ESCEO working group gives a weak rec-
ommendation that paracetamol (acetaminophen) should not be used
on a regular basis as Step 1 long-term background pharmacological
therapy for the management of knee OA.
Conversely, (3) The ESCEO working group gives a weak recom-
mendation that paracetamol (acetaminophen) at doses no greater
Table 1
Results of the GRADE assessment and summary of ESCEO recommendations for the management of knee osteoarthritis
Proportion of votes cast by ESCEO working group members completing the GRADE assessment (N = 16) (%)
Number Recommendation Strong Do Weak Do No recommendation
Weak
Don’t
Strong
Don’t
1. The ESCEO working group affords a strong recommendation to the application of a core
set comprising: information access/education, weight loss, and an exercise program,
which is applicable throughout the management of knee OA.
88% 12% 0 0 0
2. The ESCEO working group gives a weak recommendation that paracetamol
(acetaminophen) should not be used on a regular basis as Step 1 long-term
background pharmacological therapy for the management of knee OA.
69% 25% 0 0 6%
3. The ESCEO working group gives a weak recommendation that paracetamol
(acetaminophen) at doses no greater than 3 g/day may be used as short-term rescue
analgesia only, given on top of a background of Step 1 chronic therapy with
SYSADOAs.
44% 56% 0 0 0
4. The ESCEO working group affords a strong recommendation to the use of pCGS as Step
1 long-term background therapy for the management of knee OA, and discourages
the use of other glucosamine formulations.
81% 19% 0 0 0
5. The ESCEO working group affords a strong recommendation to the use of prescription
CS as Step 1 long-term background therapy, as an alternative to pCGS, and the
prescription drug should be distinguished from low quality OTC products.
81% 19% 0 0 0
6. The ESCEO working group gives a weak recommendation that a combination of
glucosamine and CS should not be used in Step 1 of background therapy, as there is
no preparation containing both prescription products and no convincing evidence
for existing non-prescription formulations.
56% 31% 6% 6% 0
7. The ESCEO working group gives a weak recommendation to the use of SYSADOAs other
than CS and pCGS (i.e. ASU and diacerein) as alternative Step 1 background therapy.
19% 69% 0 0 12%
8. The ESCEO working group affords a strong recommendation to the use of topical
NSAIDs as cyclic add-on analgesia in Step 1, for patients who are still symptomatic
after the use of Step 1 background therapy, and prior to use of oral NSAIDs.
75% 19% 6% 0 0
9. The ESCEO working group affords a strong recommendation to the use of oral NSAIDs
(selective or non-selective) as Step 2 therapy, if used only intermittently or for
longer cycles; the use of oral NSAIDs should be based on the patient risk profile.
94% 0 0 6% 0
10. The ESCEO working group affords a weak recommendation to the use of IAHA in
patients who have contraindications to NSAIDs, or if the patient is still symptomatic
despite the use of NSAIDs.
56% 44% 0 0 0
11. The ESCEO working group affords a weak recommendation to the use of IA
corticosteroids, which are more effective than IAHA in the first few weeks of
treatment in the same patient population; more severe pain may be a better
predictor of this short-term efficacy than inflammatory signs.
69% 25% 6% 0 0
12. The ESCEO working group gives a weak recommendation to the use of short-term
weak opioids in Step 3 of the treatment algorithm as the last pharmacological
attempt before surgery.
25% 75% 0 0 0
13. The ESCEO working group gives a weak recommendation to the use of duloxetine as an
alternative to weak opioids in Step 3 of the algorithm, especially in patients with
pain from central sensitization.
19% 56% 0 25% 0
14. The ESCEO working group affords a strong recommendation to total knee replacement
surgery for end-stage knee OA patients, which is a highly selective and cost-effective
procedure although not devoid of adverse outcomes; the role of other surgical
procedures, especially unicompartmental knee replacement, should be further
investigated.
81% 13% 6% 0 0
15. The ESCEO working group gives a weak recommendation to the use of classical oral or
transdermal opioids in end-stage knee OA patients for whom surgery is
contraindicated.
38% 56% 0 6% 0
Note: Strong recommendation given when >75% of votes were cast in favor of “strong do”; Weak recommendation given when <75% of votes were cast in favor of “strong do”.
ASU, avocado soybean unsaponifiables; CS, chondroitin sulfate; ESCEO, European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Dis-
eases; GRADE, Grading of Recommendations Assessment, Development and Evaluation; IA, intra-articular; IAHA, IA hyaluronic acid; NSAIDs, non-steroidal anti-inflammatory
drugs; OA, osteoarthritis; pCGS, prescription crystalline glucosamine sulfate; SYSADOA, symptomatic slow-acting drugs for OA.
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on top of a background of Step 1 chronic therapy with symptomatic
slow-acting drugs for OA (SYSADOAs).
SYSADOAs The recommended approach of the ESCEO working
group to Step 1 treatment of knee OA is to initiate background therapy
with chronic SYSADOAs (Fig. 1) [7]. However, there are many different
agents in the class of SYSADOAs including glucosamine, chondroitin,
diacerein, and avocado soybean unsaponifiables (ASU), which are sup-
ported by varying degrees of clinical efficacy data. Moreover, the avail-
ability of both over-the-counter (OTC) and prescription-grade
SYSADOA products varies widely from country to country, which can
make appropriate prescribing of SYSADOAs challenging.
Glucosamine, chondroitin and ASU are natural products. Exoge-
nous glucosamine is administered as a salt. Glucosamine hydrochlo-
ride (GHCl) is a simple molecule obtained by extraction processes,and used as a nutraceutical or OTC product. Conversely, glucosamine
sulfate is a more complex molecule, which can be obtained only by a
proprietary semi-synthetic route and stabilization process and that is
found only in the prescription drug product, i.e. prescription crystal-
line glucosamine sulfate (pCGS) [58]. Chondroitin is a high molecular
weight, long chain polymer of repetitive units, which is obtained as
chondroitin 4 and 6 sulfate (covalent binding) by different extraction
processes. Thus, multiple formulations of these agents are available,
both as prescription-grade products and nutritional supplements.
However, while all preparations may claim to deliver a therapeutic
level of glucosamine or chondroitin, not all are supported by clinical
evidence [5962]. Only pCGS is shown to deliver consistently high
glucosamine bioavailability and plasma concentration in humans,
which corresponds to demonstrated clinical efficacy [6269]. Con-
versely, GHCl and non-characterized glucosamine sulfate products
Fig. 1. Updated ESCEO stepwise treatment algorithm for knee osteoarthritis. COX-2, cyclooxygenase-2; CS, chondroitin sulfate; CV, cardiovascular; GI, gastrointestinal; GS, glucos-
amine sulfate; IA, intra-articular; NSAID, non-steroidal anti-inflammatory drug; PPI, proton pump inhibitor; SYSADOA, symptomatic slow-acting drugs in osteoarthritis; OA, osteo-
arthritis.
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a misleading “sulfate” labeling) are repeatedly demonstrated as inef-
fective in OA [62,64,7072]. Similarly, only pharmaceutical-grade
chondroitin sulfate (CS) has been evaluated for purity, content and
physio-chemical parameters [73], and clinical evidence supports only
pharmaceutical-grade CS [7477].
Thus, among all glucosamine and chondroitin products available,
the ESCEO recommends specifically the use of pharmaceutical-grade
prescription glucosamine (pCGS) and chondroitin products, for which
the evidence base is unequivocal [7]. In future, the ESCEO recom-
mends that generic preparations of complex molecules with biologi-
cal activity such as pCGS may be treated as “biosimilars” akin to the
European Medicines Agency (EMA) guidance on biological medicinal
products (EMEA/CHMP/BMWP/42,832/05 Rev.1; 2014), for which
data demonstrating comparability with the reference medicinal prod-
uct using appropriate physico-chemical and in vitro biological tests,
non-clinical studies and clinical studies must be presented [59]. It
seems likely that for all other complex molecules classed as SYSA-
DOAs, the recommendation to use only formulations clearly sup-
ported by the evidence-base should apply.
Glucosamine sulfate The ES of pCGS on pain is 0.27 (95% CI 0.12 to
0.43) [63,64], which although ‘small’, is greater than the effect of
paracetamol (ES = 0.14) and similar to the ES measured for non-ste-
roidal anti-inflammatory drugs (NSAIDs) (ES = 0.32; 95% CI 0.24, 0.39)
[46,47,78]. Conversely, other glucosamine preparations were devoid
of efficacy in high-quality trials [64], and in a recent meta-analysis of
individual patient data [71]. pCGS also has a significant effect on func-
tion [63], and there is evidence for disease-modifying effects [65,66],
reduction in need for concomitant OA medications [79,80], and a
delay in need for total joint replacement (TJR) surgery (p = 0.026)
[80]. In a new network meta-analysis including only long-term (>1
year) trials of any pharmacological intervention for knee OA, only
pCGS had a disease-modifying profile, being consistently effective on
knee OA pain (ES = 0.29,;95% credibility interval [CrI] 0.09, 0.49),
physical function and joint structure changes [81]. Furthermore, non-
prescription glucosamine formulations, including GHCl with or with-
out the addition of sodium sulfate (to get a misleading “sulfate”
claim), were not effective on any outcome. Glucosamine supplemen-
tation is generally considered as safe and is not associated with any
increased odds of AEs versus placebo [18,62,67,82,83].
GRADE recommendation: (4) The ESCEO working group affords a
strong recommendation to the use of prescription crystalline glucos-
amine sulfate (pCGS) as Step 1 long-term background therapy for the
management of knee OA, and discourages the use of other glucos-
amine formulations.
Chondroitin sulfate The ES of chondroitin 4&6 sulfate (CS) on pain
is reportedly variable [10, 61], and a recent meta-analysis found that
CS provides a moderate benefit for pain, with greater effect on func-
tion in knee OA; albeit with large inconsistency [84]. A recent study
showed that pharmaceutical-grade CS is not different to celecoxib in
terms of efficacy in symptomatic knee OA [77]. It was also reported to
provide beneficial effects on joint structure, as assessed by changes
visualized using magnetic resonance imaging [85]. The ChONdroitin
versus Celecoxib versus Placebo Trial (CONCEPT) was conducted in
full accordance with the 2015 EMA guidelines on clinical investiga-
tion in OA (CPMP/EWP/784/97 Rev. 1) [86], and found that CS
(800mg/day) and celecoxib (200mg/day) showed a greater signifi-
cant reduction in pain and Lequesne Index than placebo [77]. CS is
also shown to have an effect on joint structural changes that could be
clinically relevant [74,75]. In the network meta-analysis of long-term
trials of any medication in knee OA, prescription CS had a significant
effect on joint structure changes [81]. CS has a good safety profile at
doses up to 1200mg per day, with no significant increased odds of
AEs versus placebo [18,61,82,83].
GRADE recommendation: (5) The ESCEO working group gives a
strong recommendation to the use of prescription chondroitin sulfateas Step 1 long-term background therapy, as an alternative to pCGS,
and the prescription drug should be distinguished from low quality
over-the-counter products.
Glucosamine and chondroitin combination Glucosamine and chon-
droitin are often found in combination as dietary supplements
although the combined products may be of variable pharmaceutical
quality [87], and trials provide conflicting results as to whether there
is any additional benefit to be derived from the combination
[61,8890]. A recent RCT of 164 patients with Kellgren-Lawrence
(KL) grade 2 or 3 radiographic knee OA and moderate-severe knee
pain who received 6 months with CS (1200mg) plus glucosamine sul-
fate (1500mg) once-daily or placebo, failed to demonstrate superior-
ity of the available glucosamine/chondroitin combination over
placebo in terms of reducing joint pain and functional impairment in
patients with symptomatic knee OA over 6 months [91]. These find-
ings may be attributed to the fact that CS is known to interfere with
the absorption of glucosamine, reducing its bioavailability by
50%75% [92,93]. Thus, the combination of glucosamine and chon-
droitin may not be recommended.
GRADE recommendation: (6) The ESCEO working group gives a
weak recommendation that a combination of glucosamine and chon-
droitin sulfate should not be used in Step 1 of background therapy, as
there is no preparation containing both prescription products and no
convincing evidence for existing non-prescription formulations.
Avocado soybean unsaponifiables (ASU) ASU is a complex mixture of
many natural vegetable extracts taken from avocado and soybean oils;
the identity of the active component(s) is not known and analysis of
commercially-available ASU supplements demonstrates variation in
the sterol content [94]. In clinical studies of 3 to 6 months, some
improvement in pain, stiffness and physical function has been shown
with ASU (300mg/day) leading to reduced need for analgesia [9597],
but mixed results for the effect of ASU on disease progression were
found in studies of 23 years’ duration in patients with hip or knee OA
[98,99]. A single article (that was not subject to peer-review) has raised
some concerns of possible AEs affecting the skin, liver, GI system, and
platelet aggregation without any clear investigation of the relationship
of these AEs to ASU [100]. However, recent safety meta-analyses of a
specific proprietary ASU product have found no significant differences
for safety signals compared with placebo treatment from limited trial
evidence of ASU using concomitant NSAIDs [18,101].
Diacerein is an anthraquinone derivative with anti-inflammatory
activity [102]. In meta-analyses, diacerein has a small beneficial effect
on pain for up to 3 years, equivalent to a 9% reduction in pain (95% CI
¡16% to ¡2%) [103], with an estimated ES of 0.24 (95% CI 0.08, 0.39)
[104]. Limited benefit in delay of joint progression has been reported
in hip OA [105], but significant long-term effects in knee OA are yet
to be shown [106]. The safety of diacerein has been called into ques-
tion following reports of severe diarrhea and rare cases of potentially
serious hepatotoxicity [107]. In a recent safety meta-analysis, the
odds of any AE with diacerein was more than twice that with placebo,
with or without concomitant OA treatment, largely due to GI AEs
(diarrhea, abdominal pain, soft stools, colitis) and urine discoloration
[18]. This incidence of diarrhea after daily treatment with diacerein
100mg reportedly varies from 2.3 to 45.9%; this wide ranging result
may be partly explained by variability of products containing diacer-
ein on the market [108].
Nonetheless, a report from the EMA concluded that the benefit-risk
balance of diacerein remains positive for hip and knee OA in patients
aged<65 years [107]. It is advised that patients start treatment on half
the normal dose (i.e. 50mg daily instead of 100mg daily) and should
stop taking diacerein if diarrhea occurs. Furthermore, a recent opinion-
based report from the ESCEO supports diacerein as a background
treatment of OA, which may be of particular benefit in patients with a
contraindication to NSAIDs or paracetamol [109]. Thus, although
scarcer evidence is available, diacerein and ASU seem to offer a good
benefit: risk ratio in the management of knee OA.
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recommendation to the use of SYSADOAs other than CS and pCGS (i.e.
ASU and diacerein) as alternative Step 1 background therapy.
Topical NSAIDs may be added to the treatment regimen in Step 1 if
the patient is still symptomatic after establishing appropriate back-
ground pharmacological therapy with SYSADOAs, and rescue analgesia
with paracetamol provides insufficient symptom relief. The short-term
efficacy of topical NSAIDs in knee OA has been established in several
RCTs, meta-analyses and real-life studies [110115]. A recent network
meta-analysis found that topical NSAIDs were superior to placebo for
relieving pain (standardized mean difference [SMD] =¡0.30; 95% CI
¡0.40, ¡0.20) and improving function (SMD = - 0.35; 95% CI ¡0.45 to
¡0.24) in OA, among which diclofenac patches were most effective for
OA pain (SMD=¡0.81; 95% CI ¡1.12 to ¡0.52) [116]. Evidence from
head-to-head studies shows that topical NSAIDs are as effective as oral
NSAIDs, with a pooled ES for pain relief of 0.44 (95% CI 0.27, 0.62)
[110]. Topical NSAIDs are associated with a lower risk of systemic AEs
compared with oral NSAIDs due to lower systemic absorption [117],
albeit with an increased risk of local mild skin reactions compared
with placebo [111,114,118]. A recent safety meta-analysis found that
the increases in skin and subcutaneous tissue disorders observed with
topical NSAIDs may be product specific, as notably higher rates were
observed only with diclofenac [17]. For considerations of safety, topical
NSAIDs may be used in preference to oral NSAIDs, particularly in OA
patients aged 75 years, and those with co-morbidities or at an
increased risk of GI, CV or renal AEs.
GRADE recommendation: (8) The ESCEO working group affords a
strong recommendation to the use of topical NSAIDs as cyclic add-on
analgesia in Step 1, for patients who are still symptomatic after the
use of Step 1 background therapy, and prior to use of oral NSAIDs.
Step 2: advanced pharmacological treatment
Oral NSAIDs If Step 1 treatments show inadequate efficacy, or in
patients presenting with moderate-severe pain, benefit may be
obtained with advanced pharmacological treatments. Oral NSAIDs
have a small to moderate effect on pain relief in OA, with ES ranging
between 0.35 (95% CrI 0.31, 0.40) for OA approved daily doses of cele-
coxib 200mg/day, and 0.57 (95% CrI 0.45, 0.69) or 0.58 (95% CrI 0.43,
0.74) for maximally-approved daily doses of diclofenac 150mg/day
or etoricoxib 60mg/day [119]; cyclooxygenase-2 (COX-2) selective,
partially-selective, or non-selective (ns) NSAIDs are shown to be simi-
larly effective in controlling pain [117,120,121]. In recent meta-analy-
ses, oral NSAIDs were found to be similar to opioids for relieving pain
in OA [122,123]. A Cochrane review assessed celecoxib to be slightly
better than placebo and some nsNSAIDs in reducing OA pain and
improving function with high level of evidence [124]. However, in
the network meta-analysis of long-term trials of pharmacological
interventions in knee OA, NSAIDs were not associated with improved
pain, function or joint structure changes, with the exception of cele-
coxib which had a very small and probably not clinically relevant ES
on knee pain (SMD = 0.18, 95% CrI 0.01, 0.35), that was no longer sig-
nificant when only high-quality trials were considered [81]. In previ-
ous guidance, the selection of appropriate NSAID has been driven by
assessment of benefit: risk balance, in terms of variability in GI and
CV safety profile between individual drugs, and individual patient
characteristics affecting risk of AEs [7]. Recent meta-analyses of the
safety of NSAIDs suggests that all nsNSAIDs and COX-2 inhibitors
have the potential for GI and CV toxicity [125,126].
A meta-analysis of 280 trials of NSAIDs versus placebo (124,513
participants, 68,342 person-years) and 474 trials of one NSAID versus
another NSAID (229,296 participants, 165,456 person-years) found
that all NSAID regimens, including nsNSAIDs and COX-2 inhibitors,
increase upper GI complications compared with placebo (COX-2
inhibitors rate ratio [RR] = 1.81; 95% CI 1.17, 2.81; diclofenac
RR = 1.89; 95% CI 1.16, 3.09; ibuprofen RR = 3.97; 95% CI 2.22, 7.10;
and naproxen RR = 4.22; 95% CI 2.71, 6.56) [125]. In response to aletter requiring an analysis of these data with respect to age categori-
zation [127], the authors did not report any NSAID-specific increase
in relative risk (RR) of GI or CV major event in addition to the stan-
dard age-related GI/CV risk [128]. Another meta-analysis revealed
that COX-2 inhibitors were similar to nsNSAIDs in combination with
the gastroprotectant proton pump inhibitors (PPIs) in regard to upper
GI AEs, GI symptoms and CV AEs [129]. There was no difference in
upper GI AEs between COX-2 inhibitors and nsNSAIDs with concur-
rent use of PPIs (RR = 0.61; 95% CI 0.34, 1.09). In terms of GI toxicity,
celecoxib may be less toxic than nsNSAIDs. A retrospective pooled
analysis of 21 RCTs of 9461 patients aged65 years with OA, rheuma-
toid arthritis or ankylosing spondylitis found that the combined inci-
dence of GI AEs (abdominal pain, constipation, diarrhea, dyspepsia,
flatulence, nausea) were reported by fewer patients receiving cele-
coxib (16.7%) than with naproxen (29.4%), ibuprofen (26.5%), or diclo-
fenac (21.0%) [130].
While it was previously thought that selectivity of the NSAID for
the COX-2 enzyme governed the CV toxicity profile, recent results
suggest that CV risk may be drug specific; rofecoxib is the only NSAID
associated with an increased risk of CV events, while celecoxib is
associated with a lower incidence of stroke compared with the other
drugs in the NSAID class [131]. In a meta-analysis of 26 RCTs, the inci-
dence of the composite CV endpoint was increased with rofecoxib
when compared to all other NSAIDs (odds ratio [OR] = 1.61; 95% CI
1.31, 1.98), and to other COX-2 selective-NSAIDs (OR = 1.84; 95% CI
1.32, 2.55) [131]. The risk of myocardial infarction (MI) was increased
with rofecoxib in comparison to all other NSAIDs (OR = 1.81; 95% CI
1.38, 2.38), while a lower risk of MI was detected with celecoxib
(OR = 0.58; 95% CI 0.40, 0.86) and naproxen (OR = 0.61; 95% CI 0.38,
0.99) [131]. The incidence of stroke was increased by rofecoxib in
comparison with all NSAIDs (OR = 1.49; 95% CI 1.03, 2.16), and
decreased by celecoxib when compared with all NSAIDs (OR = 0.60;
95% CI 0.41, 0.89) [131]. A significant increased risk of hemorrhagic
stroke was also found with diclofenac (RR = 1.27; 95% CI 1.02, 1.59)
and meloxicam (RR = 1.27; 95% CI 1.08, 1.50) [132]. In the Prospective
Randomized Evaluation of Celecoxib Integrated Safety vs Ibuprofen
Or Naproxen (PRECISION) trial, celecoxib was found to be non-infe-
rior to naproxen or ibuprofen for the primary composite outcome of
CV death (including hemorrhagic death), nonfatal MI, or nonfatal
stroke [133]. A population-based cohort study has estimated the
absolute risk of MI associated with NSAID use at around 0.5% to 1%
per year [134]. Although this absolute MI risk increase is small, NSAID
use is very prevalent in older adults. In 2010, around 43 million adults
(19.0%) took aspirin at least three times per week for more than
3months (i.e. regular users), and more than 29 million adults (12.1%)
were regular users of NSAIDs [135]. The odds of acute MI for exposure
to NSAIDs taken for any duration of time, showed an increase in risk
of 15% for celecoxib (200mg), 25% for naproxen (500mg), 35% for
diclofenac (100mg), 40% for ibuprofen (1200mg), and 55% for rofe-
coxib (25mg) [134]. Notably, the MI risk with celecoxib appeared to
depend on continuously using the drug for more than 30 days,
whereas for ibuprofen, rofecoxib, diclofenac, and naproxen, a height-
ened MI risk occurred within 7 days of use [134]. A recent safety
meta-analysis of COX-2 inhibitors (celecoxib, rofecoxib, etoricoxib,
and valdecoxib) found a significant increase in CV AEs, even when
rofecoxib was excluded, specifically hypertension, congestive heart
failure and peripheral and generalized edema [20], which is consis-
tent with other findings for nsNSAIDs [136]. The risk of hospitaliza-
tion due to heart failure is roughly doubled by all NSAID regimens
(COX-2 inhibitors RR = 2.28; 95% CI 1.62, 3.20; diclofenac 1.85; 95% CI
1.17, 2.94; ibuprofen 2.49; 95% CI 1.19, 5.20; and naproxen 1.87; 95%
CI 1.10, 3.16) [125].
All NSAIDs are also associated with an increased risk of acute kid-
ney injury, which may be particularly high in the first 30 days after
initiation of therapy [137,138]. Although patients with normal renal
function are unlikely to develop acute kidney injury secondary to
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diabetes have higher chance of developing these complications [137].
Consequently, due to the risk of GI and CV events with all NSAIDs,
the ESCEO recommended in 2014 that all NSAIDs are used at the low-
est effective dose for the shortest period of time necessary to control
pain, i.e. intermittently or in longer cycles rather than in chronic use
[7]. The ESCEO working group considers that celecoxib (200mg/day)
may be the preferred oral NSAID, due to the balance between good
short-term efficacy in OA at approved doses and its lower propensity
for toxicity, especially at the GI level.
GRADE recommendation: (9) The ESCEO working group affords a
strong recommendation to the use of oral NSAIDs (selective or non-
selective) as Step 2 therapy, if used only intermittently or for longer
cycles; the use of oral NSAIDs should be based on the patient risk pro-
file, as described in Fig. 1.
Intra-articular interventions: hyaluronic acid and corticosteroids In
the case of contraindications to NSAIDs, or if the patient is still symp-
tomatic despite use of NSAIDs, intra-articular (IA) treatment may be
considered. IA hyaluronic acid (IAHA) may be a good alternative to
NSAIDs for knee OA, with a more favorable safety profile, especially
for older patients or in those at greater risk for NSAID-induced AEs.
Viscosupplementation with IAHA is an effective treatment for knee
OA with beneficial effects on pain, function and patient global assess-
ment [139]. There is good evidence for the effectiveness of HA from
RCTs, numerous meta-analyses, and real-life experience [140142].
In a network meta-analysis, IAHA had a measured ES of 0.34 on pain
(95% Crl 0.26, 0.42) when compared with IA placebo at 3 months [44].
Moreover, IAHA was the most efficacious treatment for pain among
all OA interventions [38], with superior efficacy to oral NSAIDs [143].
Accounting for the risk of bias in RCTs, the estimated ES of IAHA on
pain has been reduced to - 0.30 (95% CI ¡0.36 to ¡0.23; p < 0.001)
[144], and to ¡0.21 while retaining significance for reduction of pain
intensity at 3 months versus IA placebo (SMD =¡0.21; 95% CI ¡0.32,
¡0.10) [145]. Furthermore, systematic reviews of overlapping meta-
analyses have confirmed that IAHA is a viable option for knee OA, and
its use results in improvement in knee pain and function that can per-
sist for up to 26 weeks [146,147]. HA has a slow onset of action, with
efficacy on pain demonstrated by week 4, reaching a peak at 8 weeks
that is maintained for up to 6 months [148150]. Beyond 8 weeks
post-injection IAHA demonstrates superior, longer-lasting efficacy
than IA corticosteroids [151]. Studies demonstrate that a single injec-
tion of IAHA offers no benefit over placebo [152], that multiple injec-
tion courses are superior to a single injection (24 injections gave
the largest ES on pain at 3 and 6 months) [153], and there appears to
be no additional benefit given by a 5-injection course over a 3-injec-
tion course [154].
While the efficacy of IAHA injections has been demonstrated
across meta-analyses [155], some heterogeneity is found between tri-
als, with a few trials reporting no benefit over placebo [152,156], and
the magnitude of clinical benefit is reportedly different for different
HA products [139]. Low molecular weight (MW) HA may provide
inferior efficacy to intermediate and high MW HA [157159]. The
occurrence of AEs may also be HA product-dependent; Cross-linked
high MW HAs (hylans) have been associated with increased pseudo-
septic reactions [160], and an increased risk of local adverse reactions
(RR 1.91; 95% CI 1.043.49; I2=28%) and flares (RR 2.04; 95% CI
1.183.53; I2=0%) compared with intermediate or lowMWHA [161].
Conflicting safety reports associated with IAHA have led to some
concerns over its use [162] that were not endorsed by the ESCEO [7].
A recent meta-analysis found no significant increased odds for AEs at
any organ or system level [19]; however, the level of the evidence
was graded as “low” and “moderate”, as a lack of reporting of AEs
with IAHA was acknowledged. There were increased odds for serious
AEs found in the IAHA group versus placebo, particularly in studies
with concomitant OA treatment allowed (OR = 1.78; 95% CI 1.10,
2.89), which may require further investigation [19]. Differences in thereporting of serious AEs, whether a causal relationship was estab-
lished or not [163], may account for the disparate conclusions regard-
ing the balance of benefits and harms [164]. A network meta-analysis
of 74 studies of 18 HA products involving 13,042 patients aged 45 to
75 years found a very low incidence of AEs, of which the most com-
monly reported were transient local reactions such as pain, swelling
and arthralgia (incidence 8.5%) [165]. None of the HA products were
statistically significantly different from placebo, nor from each other
with regard to incidence of AEs. Multiple courses of IAHA are shown
to be safe up to 18 months, with an overall AE rate of 0.008 (95% CI
0.001, 0.055) [166], although further long-term studies of the safety
of IAHA are warranted.
IAHA therapy remains efficacious over several years of treatment,
and 80% of patients respond to repeat courses of IAHA injections over
3 years [167]. Retrospective database analyses demonstrating a
reduced need for, or delay in need for total knee replacement (TKR)
surgery of around 2 years, and up to 3.5 years with 5 or more courses
of IAHA [168173]. IAHA treatment also reduces the need for other
pain medications such as NSAIDs, corticosteroids and opioids among
patients with knee OA [174]. IAHA is positioned later in the treatment
algorithm, unless NSAIDs are contraindicated, due to the requirement
for repeated injections performed by a hospital practitioner, and the
inherent higher cost of treatment. Further investigation to define the
patient phenotypes associated with optimal benefit: risk for IAHA
treatment is warranted [141], and long-term efficacy should be better
substantiated in additional prospective RCTs. IAHA should only be
administered in knee OA once the acute inflammatory flare has set-
tled. In these patients, IA corticosteroids may be used to treat the
knee effusion.
IA corticosteroids are more effective than placebo and IAHA in the
short-term (24 weeks) and efficacy may be higher in patients with
more severe pain [151,175,176]. Indeed, intramuscular glucocorticoid
injection has shown a clinically relevant reduction in pain associated
with hip OA for up to 12 weeks post-injection [177]. However, limited
benefit of repeated courses of IA corticosteroids on symptoms has
been demonstrated and no benefit on joint structure modification in
the long term was seen in two 2-year studies [178].
GRADE recommendations: (10) The ESCEO working group affords a
weak recommendation to the use of IAHA in patients who have con-
traindications to NSAIDs, or if the patient is still symptomatic despite
the use of NSAIDs.
(11) The ESCEO working group affords a weak recommendation to
the use of IA corticosteroids, which are more effective than IAHA in
the first few weeks of treatment in the same patient population;
more severe pain may be a better predictor of this short-term efficacy
than inflammatory signs.
Step 3: last pharmacological treatment
Last pharmacological options for the severely symptomatic
patient are represented by short-term weak opioids, such as trama-
dol, for which there is good evidence of analgesic benefit in knee OA
[120,179]. Opioids significantly decrease pain intensity (ES ¡0.79;
95% CI ¡0.98 to ¡0.59) and have small benefit on function (ES ¡0.31;
95% CI ¡0.39 to ¡0.24), while the number needed to harm (NNT) was
calculated as 5 compared with placebo [180]. The sustained release
(SR) formulation of tramadol may be preferred to reduce AEs [181];
Furthermore, the slow upwards titration of tramadol SR from 50mg
up to 100mg is recommended to improve tolerability and minimize
treatment discontinuations due to AEs [182]. Meta-analyses have
found small beneficial effects of non-tramadol opioids on OA pain
and function but with increased safety issues, particularly in older
people (>60 years) [183,184]. A recent safety meta-analysis of oral
opioids used in OA found an increased risk of GI (dry mouth, oral
ulceration, nausea, vomiting, dyspepsia, constipation), central ner-
vous system (headache, dizziness, fatigue, somnolence), and derma-
tological AEs (rash or pruritus) compared with placebo for both
O. Bruyere et al. / Seminars in Arthritis and Rheumatism 49 (2019) 337350 345immediate-release and SR formulations [21]. Notably, treatment with
opioids is not found to be superior to treatment with non-opioid
medications for improving pain-related function [185].
The antidepressant duloxetine has been used in chronic pain syn-
dromes and some evidence for an effect is shown in OA especially in
patients with pain from central sensitization, albeit with a high rate
of AEs (dizziness, risk of falls) [186188]. Duloxetine is not widely
used in Europe, although it may be prescribed for OA.
GRADE recommendations: (12) The ESCEO working group gives a
weak recommendation to the use of short-term weak opioids in Step
3 of the treatment algorithm as the last pharmacological attempt
before surgery.
(13) The ESCEO working group gives a weak recommendation to
the use of duloxetine as an alternative to weak opioids in Step 3 of the
algorithm, especially in patients with pain from central sensitization.
Step 4: end-stage disease management and surgery
Full review and advice on surgical procedures for the management
of end-stage knee OA goes beyond the scope of the working group’s
commitment. However, TKR is appropriate when all previous modali-
ties have failed, if the patient is severely symptomatic, and there is
significant loss in quality of life [189191]. The surgical techniques
that may be employed include: total joint replacement, partial knee
replacement, or osteotomy around the knee. Recent years have seen
an increase in the number of joint replacement surgeries performed
[192], due in part to the aging population, increasing demands of
patients, and more joint replacements performed in younger patients
[193,194]. A recent network meta-analysis suggests that function
scores are improved by TKR, which has better long-term efficacy,
while unicompartmental knee replacement and osteotomy have bet-
ter efficacy in the short-term [195]. Although TKR is highly successful
and cost-effective, it has several adverse outcomes; While unicom-
partmental knee replacement has a higher revision rate, it has a lower
occurence of complications compared with TKR, including mortality
[196]. TKR may give better results when patients are carefully
selected and well informed, surgery is well performed, and rehabilita-
tion is appropriate [11].
For severly symptomatic patients in whom surgery is cotraindi-
cated, or if they are unwilling to undergo surgery, the last pharmaco-
logical resort may be classical oral or transdermal opioids which
demonstrated small to moderate positive effects on OA pain and
function albeit with an increased risk of AEs [197]; They should be
prescribed following the guidelines for use of opioid analgesics in
management of non-cancer pain [198].
GRADE recommendations: (14) The ESCEO working group affords a
strong recommendation to total knee replacement surgery for end-
stage knee OA patients, which is a highly selective and cost-effective
procedure although not devoid of adverse outcomes; the role of other
surgical procedures, especially unicompartmental knee replacement,
should be further investigated.
(15) The ESCEO working group gives a weak recommendation to
the use of classical oral or transdermal opioids in end-stage knee OA
patients for whom surgery is contraindicated.
Discussion
The 2014 ESCEO stepwise algorithm of recommendations for
management of knee OA was well-received internationally, and this
article represents a timely update based upon assessment of the cur-
rent literature (20142018) regarding efficacy and safety of all treat-
ment modalities. The ESCEO believes that the combination of
treatment modalities including non-pharmacological and pharmaco-
logical intervention remains key to the management of knee OA as
outlined in the updated treatment algorithm. While the efficacy of
non-pharmacological modalities may be considered as low, and data
on cost-effectiveness of the interventions are limited andinconclusive due to trial quality issues [40], non-pharmacological
interventions are generally considered as safe. Non-pharmacological
treatments are currently under-utilized in clinical practice [42]. To
overcome barriers to the wider acceptance of non-pharmacological
modalities, including a perceived lack of expertise of the HCP, lack of
evidence-based treatment, and suboptimal care organization [42],
the promotion of interventions according to evidence-based recom-
mendations, and improved organization of care is proposed.
As Step 1 pharmacological treatment, the ESCEO working group
advocates the use of background therapy with chronic SYSADOAs,
specifically pharmaceutical-grade pCGS and CS, for which the evi-
dence is unequivocal. Recent concerns over the safety profile of para-
cetamol raise questions over its routine, chronic use, due to
increasing evidence of GI, CV, and renal AEs [49]; thus, paracetamol
should be reserved for short-term rescue analgesia only. Topical
NSAIDs may be added to Step 1 background therapy as cyclic analge-
sia, or used in preference to oral NSAIDs, particularly in OA patients
aged 75 years, and those with co-morbidities or at an increased risk
of systemic AEs. If Step 1 treatments show inadequate efficacy, or in
patients presenting with moderate to severe pain, benefit may be
obtained with advanced pharmacological treatments, such as oral
NSAIDs.
In previous guidance, the selection of an appropriate oral NSAID
was driven by assessment of the benefit: risk balance; however,
recent meta-analyses of the safety of NSAIDs suggests that all
nsNSAIDs and COX-2 inhibitors have the potential for GI and CV tox-
icity. Oral NSAID selection should be based on the patient risk profile
and consider the level of GI or CV risk associated with each NSAID;
celecoxib (200mg/day) may be the preferred NSAID due to its better
overall safety profile.
IAHA may be a good alternative to NSAIDs for knee OA, especially
for older patients or in those at greater risk for NSAID-induced AEs or
when NSAIDs have failed, although the current evidence does not
allow for a definitive conclusion. The ESCEO working group affords a
weak recommendation to the use of IAHA injections for knee OA
patients. IAHA should only be administered in knee OA once the acute
inflammatory flare has settled, and for these patients, IA corticoste-
roids are afforded a weak recommendation to treat the knee effusion
or for more severe pain.
Last pharmacological options for the severely symptomatic
patient are represented by short-term weak opioids, such as trama-
dol, which are afforded a weak recommendation, as is duloxetine as
an alternative to weak opioids, especially in patients with pain from
central sensitization. Finally, total knee replacement surgery is appro-
priate when all previous modalities have failed, if the patient is
severely symptomatic and there is significant loss in quality of life.
Future research efforts should focus on the identification of
patient phenotypes in OA, especially in the early stages of the disease.
An ESCEO-EUGMS (European Union Geriatric Medicine Society)
working group has recently suggested possible patient profiles in OA,
including the existence of 4 clinical phenotypes: biomechanical, oste-
oporotic, metabolic and inflammatory [199]. Characterization of these
phenotypes will help to properly stratify patients with OA in clinical
trials or studies, which may in turn lead to optimization of the design
of individualized treatments for OA.
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